Australia’s Biota To Become U.S. Company Through Merger With Nabi
This article was originally published in PharmAsia News
Executive Summary
Biota and Nabi have proposed a merger that will give the Australian company access to the U.S. biotech market and increase its cash on hand.
You may also be interested in...
Daiichi Sankyo and Biota Bring Next-gen Flu Drug To Japan; Continue Search For Western Partner
TOKYO - Daiichi Sankyo has received marketing and manufacturing approval in Japan for its second-generation long-acting neuraminidase inhibitor Inavir (laninamivir), bringing encouraging news to Daiichi Sankyo and Australian partner Biota, which have faced delays in snagging an ex-Japan partner for the drug
UK Orders 10.6 Million Doses of GSK/Biota Relenza To Cope With Tamiflu-resistant Flu
PERTH, Australia - Melbourne-based Biota Holdings announced recently that partner GlaxoSmithKline has been awarded a contract by the UK Department of Health for 10.6 million treatment courses of flu drug Relenza (zanamivir). Relenza was developed by Biota and is marketed by GSK
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.